Pediatric viral infections impose a heavy burden on child health, often worsened by infection-induced gut dysbiosis. Resveratrol, a natural polyphenol with antiviral, anti-inflammatory, and microbiota-modulating properties, has been proposed to interrupt this pathogenic feedback. To our knowledge, this is the first narrative review focused on resveratrol’s antiviral activity in pediatric viral infections, concurrently evaluating its impact on the gut microbiota and their interrelationship. We synthetized preclinical and the limited available pediatric clinical data regarding resveratrol’s effect on SARS-CoV-2, respiratory syncytial virus, influenza, rotavirus, and norovirus, extracting information on the models, routes of administration, dosages, mechanisms, and outcomes. Resveratrol interferes with viral lifecycles via diverse mechanisms (modulation of host signaling cascades, capsid or structural protein interactions, and suppression of pro-viral chaperones) while concurrently reshaping the gut microbiota (reducing opportunistic taxa and enriching beneficial genera such as Bifidobacterium and Lactobacillus) leading to improved short-chain fatty acid profiles, barrier integrity, and dampened inflammation. Intranasal resveratrol in children shows clinical benefit, while oral use is underexplored and limited by poor bioavailability; adult data hint at supportive microbiome and anti-inflammatory effects if the delivery is optimized. These dual antiviral and microbiome-directed effects position resveratrol as a promising adjunct in pediatric viral disease management, though well-powered pediatric clinical trials are needed to define dosages, delivery strategies, and the contribution of microbiota-mediated synergy.

Background: Pneumoconiosis is a group of lung diseases characterized by the deposition and accumulation of dust or mineral fibers in the lung interstitium, primarily caused by occupational exposure. Methods: The aim of this study was to identify cases of pneumoconiosis induced by occupational exposure in patients living on the island of Sicily (South Italy), through the retrospective analysis of pneumoconiosis cases registered by the Reference Center for the Prevention, Diagnosis and Treatment of Interstitial Lung Diseases and Rare Lung Diseases (RCLD) of University of Catania, during the decade 2012–2022. Furthermore, the results of a screening conducted in the same 10-year period (2012–2022) on cohorts of workers potentially exposed to RCS generated by Etna’s volcanic dust are reported. Results: From the consultation of the RCLD database, there does not appear to be any correlation between pulmonary fibrosis and exposure to dust of basaltic origin. Conclusions: These data seem to be confirmed by the data of the health monitoring conducted over 10 years on 200 workers involved in different processes of working with lava stone.